https://www.selleckchem.com/products/md-224.html
9 months; log-rank P = 0.0366). Patients with baseline mutant ctDNA 2 ng·mL-1 had shorter OS than those with mutant ctDNA below this threshold (log-rank P = 0.0154). We show that pretreatment cfDNA and mutant ctDNA levels may identify mCRC patients that may benefit from regorafenib treatment.Cell migration is an essential process in health and in disease, including cancer metastasis. A comprehensive inventory of migration factors is nonetheless lacking-in part due to the difficulty in assessing migration using high-throughput techno
Beğen
Yorum Yap
Paylaş
